Concentration-targeted therapy and the future of HIV management

Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.

Dermatology and therapy·2025

Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement.

The Journal of infectious diseases·2025

Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis.

Journal of drugs in dermatology : JDD·2025

Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.

Journal of the American Academy of Dermatology·2025

Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis.

American journal of clinical dermatology·2025

Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.

The Journal of dermatological treatment·2025

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

AIDS (London, England)·2026

Sex-modulated associations between cytomegalovirus cell-associated DNA and cognition in people with HIV on ART.

AIDS (London, England)·2026

Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.

AIDS (London, England)·2026

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.

AIDS (London, England)·2026

Comparing carbon emissions from oral tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis and long-acting injectables for HIV prevention.

AIDS (London, England)·2026

The additive value of coronary calcium in identifying cardiovascular risk in ageing people with HIV.

AIDS (London, England)·2026

Sodium-Glucose Cotransporter-2 Inhibitor Use and Outcomes Following Transcatheter Aortic Valve Replacement: A Propensity-Score Matched Analysis.

Critical pathways in cardiology·2026

Integrated Transcriptomic Analyses and Experimental Validation Identify TSPO as a Mitochondria-Associated Therapeutic Target in Myocarditis.

Mediators of inflammation·2026

Self-Amplifying AIE Probe for HClO-Activatable Imaging and Antioxidative/Anti-Inflammatory Therapy of Thoracic Aortic Dissection.

Angewandte Chemie (International ed. in English)·2026

Repurposing SGLT2 inhibitors in pulmonary arterial hypertension: A multi-center longitudinal pilot study demonstrating favorable effects on risk profile and ventricular coupling.

Therapeutic advances in respiratory disease·2026

The highest clinical trial failure rate for any disease in modern medicine: How both amyloid- and non-amyloid-targeting therapies failed to alter disease course in Alzheimer's disease.

Free neuropathology·2026

Mycobacterium bovis BCG infection of the brain following intravesical BCG treatment.

ASM case reports·2026

Related Experiment Videos

Concentration-targeted therapy and the future of HIV management

Related Concept Videos

Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.

Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement.

Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis.

Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis.

Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic Dermatitis.

Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

Sex-modulated associations between cytomegalovirus cell-associated DNA and cognition in people with HIV on ART.

Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.

Comparing carbon emissions from oral tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis and long-acting injectables for HIV prevention.

The additive value of coronary calcium in identifying cardiovascular risk in ageing people with HIV.

Sodium-Glucose Cotransporter-2 Inhibitor Use and Outcomes Following Transcatheter Aortic Valve Replacement: A Propensity-Score Matched Analysis.

Integrated Transcriptomic Analyses and Experimental Validation Identify TSPO as a Mitochondria-Associated Therapeutic Target in Myocarditis.

Self-Amplifying AIE Probe for HClO-Activatable Imaging and Antioxidative/Anti-Inflammatory Therapy of Thoracic Aortic Dissection.

Repurposing SGLT2 inhibitors in pulmonary arterial hypertension: A multi-center longitudinal pilot study demonstrating favorable effects on risk profile and ventricular coupling.

The highest clinical trial failure rate for any disease in modern medicine: How both amyloid- and non-amyloid-targeting therapies failed to alter disease course in Alzheimer's disease.

Mycobacterium bovis BCG infection of the brain following intravesical BCG treatment.

Related Experiment Videos

Concentration-targeted therapy and the future of HIV management

Related Concept Videos

Related Articles